Objective-To compare the efficacy of 2 strategies that use
nystatin to prevent
thrush and Candida
esophagitis in kidney
transplant recipients. Methods-A retrospective chart review was conducted of adult kidney
transplant recipients at our center, where the protocol for prophylaxis against fungal
infection was changed in March 2013. Before the protocol change, kidney
transplant recipients received
nystatin for 1 month (before group) and after the change they received
nystatin for the duration of admission (after group). The primary outcome measure was the incidence of
thrush and Candida
esophagitis within 3 months after
transplant. Analyses were conducted on all kidney
transplant recipients (intention to treat) and on only those kidney
transplant recipients who received at least 1 dose of
nystatin (modified intention to treat). Additional data collected included the duration of
nystatin and immunosuppression regimens. The Student t test and Fisher exact test were used to calculate P values for continuous and categorical data. Results-A total of 84 kidney
transplant recipients, 42 in each cohort, were included in the analysis. The groups did not differ significantly at baseline.
Nystatin was administered for a mean of 29 days in the before group and 5.74 days in the after group. Overall, 3 kidney
transplant recipients (4%), all from the after group, experienced an episode of
thrush and no patients experienced Candida
esophagitis. Two recipients who experienced
thrush did not receive any
nystatin. Conclusions-Limiting the administration of
nystatin to the duration of admission after
transplant may be sufficient for prophylaxis of fungal
infections in kidney
transplant recipients.